Pharmacotherapeutic group: sodium salicylate
ATCvet code: QN02BA04
Pharmacodynamic properties
Sodium salicylate is a NSAID and has an anti-inflammatory effect. The mode of action is based on inhibition of the enzyme cyclooxygenase, resulting in decreased production of prostaglandin (inflammation mediators).
Pharmacokinetic properties
In turkeys, orally administered sodium salicylate is absorbed by passive diffusion partially from the stomach and mainly from the small intestine. The passage through the crop influences the absorption rate and initial sodium salicylate plasma levels depend on how full the crop is. After administration into the crop maximum plasma concentrations are reached in approximately three hours (average), t1/2 is approximately two hours. When dosed orally via the drinking water (dose of 100 mg/kg body weight per day for three days) average plasma concentrations above 20 μg/ml are achieved.
Sodium salicylate distributes very well to the various tissues; the highest concentrations are reached in the liver, kidneys and lungs. Accumulation in inflammatory exudate could be detected. Further studies on metabolism are not available for the turkey. Excretion is probably primarily renal.